MSLE
Satellos Bioscience Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$134.72M
P/E Ratio
—
EPS
$-1.95
Beta
1.19
52W High
$13.39
52W Low
$5.30
50-Day MA
$8.09
200-Day MA
$8.46
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company is headquartered in Toronto, Canada.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.48M |
| EBITDA | $-35.82M |
| Operating Margin | 0.00% |
| Return on Equity | -70.50% |
| Return on Assets | -41.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.88 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 4.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $21.22M |
| Float | $18.02M |
| % Insiders | 6.37% |
| % Institutions | 49.67% |
Historical Volatility
HV 10-Day
84.56%
HV 20-Day
78.79%
HV 30-Day
69.62%
HV 60-Day
65.16%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($24.17 target)
2
Strong Buy6
BuyTurn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MSLE and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026